Hasten Bio Pays $322 Million for China Rights to Five Takeda Drugs

Hasten Biopharmaceutic will pay $322 million for rights to commercialize five Takeda Pharma's prescription cardiovascular and metabolism products in China . Formed three months ago, Hasten is backed by Ray Capital Management, an investment fund associated with Hefei City , Hasten's headquarters. The Takeda portfolio generated $110 million in China sales last year. Following its $59 billion acquisition of Shire in 2018, Takeda has divested itself of more than $13 billion of assets to improve its balance sheet. The company narrowed its focus to products for gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. More details.... Share this with colleagues: // //